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In Brief
A chemical proteomics approach lays out
a global lipid-protein interaction map and
provides evidence for the broad
druggability of lipid-binding proteins in
cells.
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Lipids play central roles in physiology and disease,
where their structural, metabolic, and signaling func-
tions often arise from interactions with proteins.
Here, we describe a set of lipid-based chemical
proteomic probes and their global interaction map
in mammalian cells. These interactions involve hun-
dreds of proteins from diverse functional classes
and frequently occur at sites of drug action. We
determine the target profiles for several drugs across
the lipid-interaction proteome, revealing that its li-
gandable content extends far beyond traditionally
defined categories of druggable proteins. In further
support of this finding, we describe a selective ligand
for the lipid-binding protein nucleobindin-1 (NUCB1)
and show that this compound perturbs the hydrolytic
and oxidative metabolism of endocannabinoids in
cells. The described chemical proteomic platform
thus provides an integrated path to both discover
and pharmacologically characterize a wide range of
proteins that participate in lipid pathways in cells.
INTRODUCTION
Small-molecule metabolites are central components of life,
where their biological functions are often mediated and regu-
lated by interactions with proteins. These metabolite-protein
interactions include ligand-receptor, substrate-enzyme, and
client-carrier relationships, many of which represent key nodes
in biochemical networks that regulate cell physiology and dis-
ease. Eukaryotic and prokaryotic cells harbor numerous struc-
turally distinct metabolites, and, among these natural products,
lipids display a prominent capacity to interact with and affect
the functions of proteins (Muro et al., 2014). Sterol metabolites,
for instance, interact with a broad set of enzymes, carriers, and
receptors to regulate the composition and structure of cell mem-
branes, as well as physiological processes, such as inflamma-
tion, metabolism, and blood pressure (Russell, 2009; Brown
and Goldstein, 2009; Evans and Mangelsdorf, 2014).
Many fatty-acid-derived lipids, including both phospholipids
and neutral lipids, are also regulated by discrete enzymatic and
transport pathways and transmit signals through an array of1668 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.nuclear hormone receptors and G-protein-coupled receptors
(GPCRs) (Evans and Hutchinson, 2010; Evans and Mangelsdorf,
2014). Lysophospholipids, for instance, have important roles in
regulating immune and nervous system function (Mutoh et al.,
2012; Shimizu, 2009), and their receptors have emerged as
drug targets for diseases such as multiple sclerosis (Urbano
et al., 2013). Oxidatively modified arachidonic acid (AA) metabo-
lites, or eicosanoids, including prostaglandins and leukotrienes,
serve as central mediators of pain and inflammation, cardiovas-
cular function, and parturition (Harizi et al., 2008), inspiring the
development of drugs that target proteins involved in eicosanoid
production and signaling (Samad et al., 2002). Additional arach-
idonoyl metabolites include the endocannabinoids N-arachido-
noyl ethanolamine (anandamide or AEA) and 2-arachidonoyl
glycerol (2-AG), which are endogenous ligands for the cannabi-
noidCB1andCB2GPCRs (Mechoulamet al., 1998), andoxidized
variants of these endocannabinoids—prostamides and prosta-
glandin esters, respectively—which represent an emerging class
of inflammatory mediators (Rouzer and Marnett, 2011).
The established and emerging functions for lipids in mamma-
lian biology, along with the substantial number of drug targets
that are lipid-binding proteins, indicate that mapping the full
complement of lipid-protein interactions in cells has the potential
to uncover newmodes of signaling that are amenable to pharma-
cological perturbation. Inspired by this idea, we describe herein
a set of chemical proteomic probes to characterize the lipid-pro-
tein interaction landscape of mammalian cells and its sensitivity
to drug action. We show that lipid probes can be used for (1)
enrichment and identification of hundreds of lipid-binding pro-
teins; (2) proteome-wide in situ engagement assays to determine
the targets and off-targets of drugs that impact lipid biology;
and (3) high-throughput screening to identify small-molecule
ligands for lipid-binding proteins. Using these methods, we
provide evidence for the broad ligandability of the lipid-interac-
tion proteome and exemplify this concept through development
of selective ligands for a lipid-binding protein nucleobindin-1
(NUCB1) that perturb endocannabinoid and eicosanoid meta-
bolism in cells.
RESULTS
Chemical Proteomic Probes for Mapping Lipid-Protein
Interactions
Chemical proteomic probes provide a versatile approach to
globally map the cellular targets of both natural and unnatural
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Figure 1. Chemical Proteomic Probes for
Mapping Lipid-Binding Proteins in Cells
(A) Structures of lipid probes featuring arach-
idonoyl (AEA-DA, AA-DA and A-DA), oleoyl (OEA-
DA and O-DA), palmitoyl (PEA-DA), and stearoyl
(S-DA) acyl chains, as well as photoreactive (dia-
zirine) and alkyne groups.
(B) AEA-DA and A-DA probes show overlapping
but distinct protein interaction profiles in HEK293T
cells. Cells were treated with each probe (20 mM)
for 30 min in situ before photocrosslinking and
analysis of probe-modified proteins as described
in Figure S1.
(C) Arachidonoyl probe labeling of membrane and
soluble proteins depends on UV irradiation of cells.
(D) Comparative labeling profiles of lipid probes
(20 mM, 30 min) in HEK293T cells. Red and blue
arrows mark representative proteins preferentially
labeled by arachidonoyl and oleoyl/palmitoyl
probes, respectively. See Figure S1C for profiles of
A-DA, O-DA, and S-DA.small molecules in native biological systems (Lee and Bogyo,
2013; Simon et al., 2013; Su et al., 2013). Some probes rely
on innate chemical reactivity with protein residues, whereas
others exploit binding affinity and light-induced crosslinking re-
actions to capture proteins (Heal et al., 2011). The latter group
typically possesses (1) a photoreactive element that converts
reversible small molecule-protein interactions into stable, cova-
lent adducts uponUV light irradiation; (2) an alkyne, which serves
as a sterically minimized surrogate reporter allowing late-stage
conjugation to azide tags by copper-catalyzed azide-alkyne
cycloaddition (CuAAC or ‘‘click’’) chemistry (Rostovtsev et al.,
2002); and (3) a binding element that directs the probe toward
proteins that recognize specific structural features (Haberkant
et al., 2013; Hulce et al., 2013; Li et al., 2013). With the goal of
identifying proteins that interact with fatty-acid-derived lipids in
cells, we prepared a set of probes that contain a diazirine photo-
reactive group, an alkyne handle, and binding groups that
resembled common fatty acids, including arachidonic (C20:4),
oleic (C18:1), palmitic (C16:0), and stearic (C18:0) (Figure 1A).
Within the arachidonoyl subset of probes, we synthesized
both fatty-acid- and fatty-acid-amide-based probes (AA-DA
and AEA-DA, respectively) and evaluated their potential to
bind and covalently modify (under UV light exposure) proteinsCell 161, 1668–168in human cells by gel-based profiling.
HEK293T cells were treated with probe
(AA-DA or AEA-DA; 20 mM, 30min), irradi-
atedwith UV light (10min, 4C), and lysed,
and the cell proteomes were fractionated
into membrane and soluble components
by centrifugation prior to conjugation to
a fluorescent reporter tag (Rh-N3) using
CuAAC (Figure S1A). Analysis of probe
targets by SDS-PAGE and in-gel fluo-
rescence scanning revealed distinct
protein-labeling profiles for each probe
(Figure S1B). The AA-DA probe showed
almost exclusive labeling of membraneproteins, which we suspected was a consequence of rapid
sequestration of this probe into membranes through its meta-
bolic incorporation into phospho/neutral-lipids or into lipidated
proteins, as has been noted for other fatty acid probes (Haber-
kant et al., 2013; Tate et al., 2015). In contrast, the AEA-DA probe
showed substantial labeling of both soluble and membrane pro-
teins in HEK293T cells (Figure S1B). The distinct labeling profile
of the AEA-DA probe likely reflects the more limited capacity of
the cell to metabolize this amidated probe, which must undergo
enzyme-mediated hydrolysis prior to incorporation into other
lipids or proteins. We therefore selected the fatty acid amide
probes for chemical proteomic mapping of lipid-binding proteins
in cells.
We also prepared a set of lipid probes that featured intact acyl
chains and a diazirine-amide head group (A-DA; O-DA, S-DA;
Figure 1A). By including members with diazirines at distinct loca-
tions (acyl chain or head group), the lipid probe set thus had the
potential, in our minds, to provide amore comprehensive portrait
of interacting proteins. Consistent with this hypothesis, the AEA-
DA and A-DA probes showed distinct protein labeling profiles in
HEK293T cells (Figure 1B). Importantly, the protein-labeling
events for both probes were UV light dependent, confirming
that they reflect reversible binding interactions between the0, June 18, 2015 ª2015 Elsevier Inc. 1669
probes and cellular proteins (Figure 1C). The polyunsaturated
arachidonoyl probes (AEA-DA and A-DA) also showed more
extensive proteomic labeling profiles compared to the monoun-
saturated (OEA-DA, O-DA) or saturated (PEA-DA, S-DA) lipid
probes (Figure 1D and Figure S1C). Based on these results
and the diverse functional roles played by arachidonate-derived
lipids in mammalian biology (Harizi et al., 2008; Rouzer and Mar-
nett, 2011), we focused our initial MS-based proteomic studies
on mapping the proteins that interact with the arachidonoyl lipid
probes (AEA-DA and A-DA) in cells.
Landscape of Lipid-Binding Proteins in Cells
We identified the protein targets of the AEA-DA and A-DA probes
using stable-isotope labeling by amino acids in cell culture
(SILAC) and liquid chromatography-tandem mass spectrometry
(LC-MS/MS) following previously developed protocols (Hulce
et al., 2013; Ong et al., 2002). Isotopically ‘‘light’’ cells served
as a static control for each experiment and were treated with
either AEA-DA or A-DA (20 mM, 30 min) before UV irradiation
(Figure S2A). Isotopically ‘‘heavy’’ cells served as comparison
groups and were treated with (1) the same conditions as the
‘‘light’’ cells (probe-versus-probe control); (2) the same probe
as the ‘‘light’’ cells but were not crosslinked with UV light
(probe-versus-no UV); or (3) the corresponding oleoyl (18:1,
OEA-DA or O-DA) or fully saturated (C16:0, PEA-DA; C18:0,
S-DA) probes. Performing these SILAC experiments in both hu-
man (HEK293T) and mouse (Neuro2a) cell lines provided an
extensive inventory of lipid probe targets—defined as proteins
with at least three unique quantifiable peptides that were labeled
by either A-DA or AEA-DA in a UV-dependent manner (SILAC
ratio R 3.0 in probe-versus-No UV experiments) and not en-
riched in probe-versus-probe control experiments (SILAC ratio <
2.0) (Figures 2A and S2B).
More than 1,000 proteins in total were enriched fromHEK293T
and Neuro2a cells by the AEA-DA and A-DA probes. Although
each arachidonoyl probe shared several hundred common tar-
gets, a large set of probe-specific targets were also identified
for both AEA-DA and A-DA (442 and 317, respectively; Fig-
ure 2B), emphasizing the value of employing both probes to
maximize the capture of lipid-binding proteins. Of note, we found
that the AEA-DA and A-DA probes targeted greater numbers of
soluble and membrane proteins, respectively (Figure 2C), which
was also manifested in the corresponding enrichment of these
protein targets in cytoplasmic/nuclear and endoplasmic reticu-
lum (ER) compartments (Figure 2D). These differences could
reflect the higher lipophilicity (i.e., cLogP) of the A-DAprobe, pro-
moting its localization in membranes.
Categorizing the lipid probe targets in relation to their functions
in biological pathways revealed enrichment of proteins involved
in protein transport, lipidmetabolism, and host-virus interactions
(Figure 2E). Analysis of the probe targets through theOMIMdata-
base further revealed links to numerous diseases, including
metabolic disorders, cancer, and cardiovascular and neurolog-
ical disease (Figure S2C). Proteins from a variety of functional
classes were enriched by each lipid probe, with particularly
high proportions of enzymes and transporters (Figure 2F). Prom-
inent among these targets were enzymes and lipid carriers
involved in fatty acid uptake (SCARB1), transport (SLC25A20),1670 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.biosynthesis (FASN and PNPLA2), and catabolism (ACADs and
HADHA) (Figure 2G). Other known arachidonoyl lipid carrier
proteins (e.g., FABP5) (Kaczocha et al., 2009) and metabolizing
enzymes (e.g., PTGS1 or COX1) were also enriched. Of particular
interest was the large number of poorly characterized proteins
lacking prior links to lipid biology that were strongly enriched by
at least one of the arachidonoyl probes (Table S1). Consistent
with our gel-based profiles (Figures 1D and S1C), we found
that most lipid probe targets were preferentially enriched by the
AEA-DA and A-DA probes compared to either monounsaturated
(OEA-DA, O-DA) or saturated (PEA-DA, S-DA) probes (Figures
2H, S2D, and S2E and Table S1)
Validation and Characterization of Lipid Probe-Protein
Interactions
We next sought to validate representative probe-protein inter-
actions and selected six probe targets, including both known
(e.g., PTGR2) and unannotated (e.g., NUCB1 and NENF) lipid-in-
teracting proteins that displayed varying degrees of preferential
labeling by the AEA-DA versus PEA-DA probes (Figures 3A and
3B). In situ probe treatment of HEK293T cells expressing Myc-
tagged proteins confirmed, in each instance, the protein-lipid
interaction (Figures 3C and S3A). NUCB1, NENF, and ZADH2
were each labeled by AEA-DA to a greater degree than PEA-
DA, whereas ALDH1B1, VAT1, and PTGR2 exhibited similar
extents of interaction with each probe, matching, in general,
the lipid interaction profiles observed for endogenous forms of
these proteins (compare Figures 3B and 3C).
NENF, also called neudesin, is a secreted protein from the cy-
tochrome b5-like heme/steroid-binding family that promotes the
survival of neurons (Kimura et al., 2008). NENF has been shown
to bind hemin and protoporphyrin IX (Pp-IX), and these interac-
tions can promote neurotrophic activity (Kimura et al., 2008);
however, whether NENF can also bind steroids/lipids remains
unknown. We found that hemin and Pp-IX inhibited in a concen-
tration-dependent manner the labeling of recombinant NENF by
the AEA-DA probe (Figure 3D), and the hemin-NENF interaction
(IC50 = 2 mM), in particular, appeared selective, as other AEA-DA-
modified proteins detected by SDS-PAGE were unaffected by
hemin treatment (Figure S3B). AA and, to a lesser degree, AEA,
but not 2-AG, also competitively blocked AEA-DA probe labeling
of NENF (Figure 3D).
The nucleobindin proteins NUCB1 and NUCB2 are not known
to bind small-molecule ligands, but NUCB1 has been shown to
interact physically with the prostaglandin biosynthetic enzymes
PTGS1 and PTGS2 enzymes and enhance PTGS2-mediated
prostaglandin synthesis (Ballif et al., 1996; Leclerc et al., 2008).
We found that AEA-DA probe labeling of recombinant NUCB1
was preferentially blocked by arachidonoyl lipids (AEA, AA,
and 2-AG) over saturated/shorter chain analogs [OEA, PEA, ole-
amide (ONH2)] and prostaglandins (Figure 3E). Nucleobindins
also feature two EF-hand domains that undergo conformational
changes upon binding calcium ions (de Alba and Tjandra, 2004).
Using both purified, recombinant NUCB1 (Figure 3F) and
NUCB1-transfected HEK293T cell lysates (Figure S3C), we
found that CaCl2 (100 mM) significantly and selectively increased
AEA-DA probe labeling of NUCB1, whereas EDTA appeared to
reduce this interaction.
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Figure 2. Mapping Protein Targets of Lipid Probes by Quantitative Proteomics
(A) Heavy/light SILAC ratio plots for total proteins identified in experiments comparing the labeling profiles of lipid probes (20 mM) versus a ‘‘no UV’’ control (20 mM
probe without UV irradiation) or the equivalent probe (both heavy and light cells treated with 20 mM of the same probe) in HEK293T cells. Dashed lines mark
threshold ratio values (R3-fold in no UV experiments) for designation of lipid probe targets (also see Figure S2).
(B) Venn diagram of shared and unique protein targets of AEA-DA and A-DA probes in HEK293T and Neuro2a cells.
(C–F) Analysis of lipid probe targets based on (C) presence (membrane) or absence (soluble) of known/predicted transmembrane domains; (D) known/predicted
subcellular distribution; (E) involvement in specific biological processes; and (F) protein class distribution. Categories were assigned based on UniProt anno-
tations. Data in (C) are presented as the mean percentage of total probe targets ± SEM; n = 4/group. **p < 0.01 for AEA-DA versus A-DA probe targets.
(G) Diagram highlighting lipid probe targets (red) in major fatty acid metabolic pathways. SILAC ratios from probe-versus-no UV experiments are indicated in
parentheses next to gene names (data shown are for the A-DA probe in HEK293T cells except for CPT1A, which was detected with the A-DA probe in Neuro2a
cells). For instances where multiple isoforms of a given protein are enriched (i.e., ACSL and GPAT), the highest ratio across all isoforms is presented.
(H) Heatmap showing the relative protein enrichment values for the AEA-DA probe compared to OEA-DA and PEA-DA probes, as well as compared to the AEA
probe itself with (AEA-DA) or without UV irradiation (no UV) as controls, in HEK293T cells. See Figure S2D for a similar analysis of the A-DA probe series and Table
S1 for complete list of lipid probe targets.In Situ Drug Profiling with Lipid Probes
We found that the lipid-interaction proteome was substantially
enriched in known drug targets (25%, or 280 proteins; Fig-
ure 4A and Table S2) compared to the total fraction of the human
proteome represented in the DrugBank database (12%). The
fraction of DrugBank proteins present among membrane and
soluble probe targets was similar (Figure S4A; 18% and 29%,respectively) and included proteins frommultiple functional clas-
ses, such as enzymes (e.g., LSS, PTGS1, and SOAT1), trans-
porters (e.g., ABCB1, ATP4A, and VDAC1-3), and receptors
(e.g., SCARB1 and PGRMC1). The remaining lipid-probe targets
not found in DrugBank included proteins that would be consid-
ered ‘‘ligandable’’ (e.g., enzymes, receptors, etc.), as well as a
large number of proteins not predicted to interact with smallCell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc. 1671
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B Figure 3. Experimental Validation of Repre-
sentative Lipid Probe Targets
(A) SILAC ratio plot for AEA-DA versus PEA-DA
(20mM)probe labeling inHEK293Tcells highlighting
targets selected for experimental validation.
(B) Representative peptide MS1 chromatograms
for selected targets showing relative labeling by
AEA-DA and PEA-DA probes.
(C) Lipid probe labeling of myc-tagged recombi-
nant proteins expressed by transient transfection
in HEK293T cells. Top panels show in situ labeling
profiles for the AEA-DA and PEA-DA probes with
indicated targets (lane 1, mock-transfected cells;
lanes 2 and 3, target-transfected cells; see Fig-
ure S3A for full gel profiles). Middle panels show
anti-myc blotting. Bottom panels show anti-actin
blotting as a loading control.
(D) Top panel shows in vitro competition profiles
of AEA-DA probe labeling of NENF by hemin,
protoporphyrin IX (Pp-IX), and the arachidonoyl
lipids AA, AEA, and 2-AG (1–100 mM) (experiments
performed in NENF-transfected HEK293T lysates).
Bottom panel shows concentration-dependent
inhibition of AEA-DA labeling of NENF by hemin
(CI = 95% confidence interval) as determined from gel profiles. Data represent mean values ± SD from three independent experiments.
(E) In vitro competition profiles of NUCB1 labeling by the AEA-DA (5 mM) probe using various lipids (203) as competitors. Experiments were performed in lysates
from NUCB1-transfected HEK293T cells.
(F) Calcium-dependent enhancement of NUCB1 labeling by the AEA-DA probe. Data represent mean values ± SEM; n = 3/condition. ***p < 0.001 for untreated
versus CaCl2 (100 mM)-treated samples.molecules based on their ascribed biochemical activities or lack
of functional characterization (Figure 4A and Table S2). These
findings suggested that the lipid probes exhibit a preferential
capacity to interact with known drug-binding proteins in cells
and, by extension, might facilitate the discovery of many addi-
tional proteins with the potential to bind small-molecule ligands.
Further, for ligandable proteins known or identified herein, we
surmised that the lipid probes could provide a method to
determine drug target engagement and the selectivity of these
interactions in cells. We set out to test these concepts by first
evaluating whether the lipid probes competed for drug binding
to DrugBank proteins in cells.
The prostaglandin biosynthetic enzymes PTGS1 and PTGS2
were selected for initial analysis, as dual PTGS1/PTGS2 and se-
lective PTGS2 inhibitors have been developed for treating inflam-
matory disorders. PTGS1 was detected as a lipid probe target in
Neuro2A cells (Figure S4B), while PTGS2 was evaluated in phor-
bol-12-myristate-13-acetate (PMA)-stimulated A549 cells (Fig-
ures S4C and S4D). We generated drug-competition profiles
with the lipid probes by co-treating heavy and light cells with
the A-DAprobe (5 mM) and either DMSO (light) or drug competitor
(25 mM; heavy) for 30 min (Figure 4B). The cells were then
irradiated with UV light, harvested, and lysed, whereupon the
heavy and light proteomes were mixed in equal proportions.
Following CuAAC conjugationwith biotin-N3, streptavidin enrich-
ment, andon-bead trypticdigestion, probe-labeledproteinswere
analyzed by LC-MS/MS. Drug-competed proteins were defined
as those showing a substantial (R3-fold) reduction in signal in
drug-treated (heavy) versus DMSO-treated (light) cells. The dual
PTGS1/2 inhibitor (±)-flurbiprofen competitively blockedA-DA la-
beling of both PTGS1 and PTGS2 in cells, whereas the selective1672 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.PTGS2 inhibitor rofecoxib disrupted A-DA labeling of PTGS2,
but not PTGS1 (Figure 4C). Both drugs showed good selectivity
for PTGS enzymes, which were among the most competed pro-
teins across the hundredsof A-DAprobe targetsdetected inNeu-
ro2A and A549 cells (Figure 4D and Table S2). Some additional
competed targets were also identified, including aldose reduc-
tase-related protein 2 (AKR1B8), which showed strong reduc-
tions in A-DA labeling in rofecoxib-, but not (±)-flurbiprofen-
treated Neuro2A cells (Figure 4D and Table S2). AKR1B8 is a
mouse ortholog of the human aldo-keto reductase AKR1B10,
which is modified and inhibited by electrophilic prostaglandins
(Dı´ez-Dacal et al., 2011), providing further support that these en-
zymes specifically interact with arachidonoyl-related lipids and
drugs.
We next expanded our analysis of drug action in cells to
include several additional lipid probe targets with known li-
gands—sterol O-acyltransferase (SOAT1), nicotinamide phos-
phoribosyltransferase (NAMPT), lanosterol synthase (LSS), and
multidrug resistance protein 1 (ABCB1) and their respective
ligands, avasimibe, FK-866, Ro 48-8071, and elacridar (Fig-
ure 5A). Some of these targets were chosen because they are in-
tegral membrane proteins (LSS, SOAT1, and ABCB1) and thus
pose technical challenges for other drug-interaction profiling
methods that measure ligand-induced changes in proteolytic
(Lomenick et al., 2009) or thermal (Martinez Molina et al., 2013)
stability. Each ligand was initially assayed at 25 mM in Neuro2a
cells, as this concentration was predicted to fully engage the
primary drug target and also facilitate a broader prospecting of
the lipid-interaction proteome for other ligandable proteins. We
tested one drug—Ro 48-8071—across a broader concentration
range (5 and 50 mM) to assess the potency of its interactions and
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Figure 4. The Lipid-Interaction Proteome Is Rich in Drug Targets
(A) Categorization of lipid probe targets based on distribution in DrugBank (left pie chart) and further analysis of non-DrugBank targets by protein classes
considered ligandable (e.g., enzymes, receptors, transporters) or not (others).
(B) Scheme for in situ competitive profiling of ligands using lipid probes. Isotopically light and heavy cells are treated with vehicle (DMSO) or competitor ligand,
respectively, along with a lipid probe for 30 min. Cells are then UV irradiated and lysed, and light and heavy lysates are combined, enriched, and digested for
LC-MS/MS analysis. Ligand targets are designated as proteins that show light/heavy ratios ofR3.0.
(C) Chemical structures of the dual PTGS1/2-inhibitor (±)-flurbiprofen and PTGS2-selective inhibitor rofecoxib and representative peptide MS1 chromatograms
for PTGS1 and PTGS2 in Neuro2a and A549 cells, respectively, showing that (±)-flurbiprofen (25 mM) competes A-DA (5 mM) labeling of both PTGS1 and PTGS2,
whereas rofecoxib (25 mM) selectively competes PTGS2 labeling.
(D) SILAC ratio plots for in situ competition experiments of A-DA (5 mM) labeling by (±)-flurbiprofen (25 mM) and rofecoxib (25 mM) showing target engagement and
selectivity across PTGS isoforms and other lipid probe targets.to facilitate identification of additional drug-protein interactions.
As before, we treated heavy and light cells with drug and DMSO,
respectively, together with the arachidonoyl probes (5 mM).
Following UV irradiation and proteomic analysis, we observed
clear evidence of engagement with the primary established
targets for each drug and, notably, little cross-reactivity with
the targets of the other drugs tested (Figures 5B and S5A).
One exception was FK-866, which competed probe labeling of
both its established target NAMPT and ABCB1B (Figure 5B).
A greater survey of the lipid-interaction proteome revealed a
unique set of additional targets for each drug (Figures 5C and
S5A), many of which were preferentially competed by one of
the four tested drugs (Figure 5D). Clear concentration-depen-
dent increases in the target landscape were observed for Ro
48-8071, with the principal target, LSS, being fully competed
at 5 mM, along with only two prominent off-targets (TMEM97and EBP), whereas, at 50 mM, Ro 48-8071 suppressed probe
labeling of many additional targets (Figures 5C and S5A). We
also compared the drug competition profiles to that of the
endogenous lipid transmitter AEA tested at 200 mM, which was
found to be a suitable concentration for competitive profiling
by gel-based analysis (Figure S5B). AEA competed several tar-
gets of the drugs FK-866 (e.g., PTGR2) and Ro 48-8071 (e.g.,
DHRS1), both of which possess lipid-like scaffolds, but not the
targets of avasimibe or elacridar (Figure 5E).
Additional profiling of drugs in Neuro2a and A549 cells using
both A-DA and AEA-DA probes to maximize coverage provided
a rich set of competed targets (Table S3). Only 30% of the
identified drug targets were listed in DrugBank, and, of the
non-DrugBank targets, a substantial portion (40%) were un-
characterized proteins or proteins that belonged to classes
that would traditionally be considered challenging to ligandCell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc. 1673
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Figure 5. In Situ Drug Profiling with Lipid Probes
(A) Structures of compounds analyzed by competitive profiling with lipid probes.
(B) Heatmap showing SILAC ratios for primary targets of drugs (25 mM, except for Ro 48-8071, which was assayed at 5 mM) from competition profiling exper-
iments performed in Neuro2a and A549 cells. All drugs were profiled in both cell lines, and target engagement for SOAT1, NAMPT, and ABCB1B is shown for
Neuro2a cells with the AEA-DA probe (5 mM) and, for LSS, in A549 cells with the A-DA probe (5 mM) (also see Table S3).
(C) Box-whisker plots of protein SILAC ratios from in situ competition experiments showing on- (red) and off- (blue) targets (ratiosR 3.0) for tested drugs.
(D) Heatmap of competed off-targets for tested drugs measured with the AEA-DA probe in Neuro2a cells.
(E) Plot of SILAC ratios from AEA-DA competition experiments with tested drugs (25 mM) versus the lipid competitor AEA (200 mM). For simplicity, only the highest
drug competition SILAC ratio is plotted for each target.
(F) Categorization of drug-competed lipid probe targets based on their presence or absence in DrugBank and by protein class (also see Table S3).based on their sparse representation in DrugBank (Figure 5F and
Table S3). Some proteins interacted strongly withmultiple drugs,
such as ferrochelatase (FECH), which was recently found to bind
kinase inhibitors in cells using thermal proteome profiling (Savit-
ski et al., 2014). Arachidonoyl probe labeling of FECH, along with
ABCB1B and TMEM97, was blocked by elacridar at concentra-
tions as low as 0.5 mM (Figure S5D), indicating that these drug-
protein interactions are high-affinity events. We confirmed that
both elacridar and Ro 48-8071 block AEA-DA probe labeling of
recombinantly expressed TMEM97 in transfected HEK293T cells
(Figure S5C). These data suggest that FECH and TMEM97 are
highly ligandable proteins, as reflected by their capacity to
interact with multiple small-molecule chemotypes in cells.
Discovery of Selective Ligands for the Lipid-Binding
Protein Nucleobindin 1
Although investigating the proteome-wide interactions of known
drugs provides one path for discovering ligand-binding proteins,
this approach is limited in throughput. We therefore asked
whether the lipid probes could be adapted for the screening of
larger compound libraries. As a proof-of-principle, we selected
NUCB1, which, we hypothesized, based on its interactions
with PTGS enzymes and preferential binding to arachidonoyl1674 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.probes, to play a role in lipid metabolism in cells. We first synthe-
sized a fluorescent arachidonoyl lipid probe (Fl-AEA; Figure 6A)
and confirmed that it bound to recombinant, purified human
NUCB1 (hNUCB1) protein to produce a substantial increase in
fluorescence polarization (FluoPol) signal (Figure 6B). This Fluo-
Pol signal was significantly reduced by arachidonoyl, but not by
palmitoyl (Figure 6C) or other (Figure S6A) competitor lipids,
recapitulating the selectivity observed by gel- and MS-based
profiling with the photoreactive lipid probes (Figure 3E).
The FluoPol assay was optimized (Z0 score of > 0.5 compared
to assays performed with AA as a competitor ligand; Figure 6B)
and used to screen 16,000 compounds from the Maybridge li-
brary at 10 mM in 384 well-plate format. Chemoinformatic anal-
ysis to remove frequent hit compounds and compounds with
structural alerts yielded 100 compounds that produced a 20%
or greater reduction in FluoPol signal (on par or greater than
the reduction caused by AA; Figure 6D). These hits were assayed
by gel-based competitive profiling with the AEA-DA probe
against recombinant hNUCB1 doped into HEK293T cell lysates,
and hydrazide 1 (Figure 6E) was identified as a strong competitor
of NUCB1 labeling (Figures 6F and S6B). Optimization of this
compound (Figure S6) furnished N-methylpiperazine amide
MJN228 (11; Figure 6G), which blocked AEA-DA probe labeling
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Figure 6. Adapting Lipid Probes for HTS to Discover NUCB1 Ligands
(A) Structure of Fl-AEA probe.
(B) Incubation of the Fl-AEA probe (0.5 mM) with recombinant human NUCB1 (1.0 mM) produced a strong FluoPol signal that was significantly suppressed by the
competitor lipid AA (20 mM; Z0 = 0.54).
(C) Concentration-dependent suppression of the NUCB1-FluoPol signal by arachidonoyl lipids AEA, 2-AG, and AA, but not palmitoyl lipids PEA, 2-palmitoyl
glycerol (2-PG), or palmitic acid (PA). Error bars represent SD (n = 5). See Figure S6A for profiling of additional lipids.
(D) Screen of 16,000 compounds identified small molecules that inhibited the NUCB1-FluoPol signal by 20% or greater (dotted black line).
(E) Structure of confirmed HTS hit 1 and positions modified for medicinal chemistry optimization. See Figures S6B–S6D for summary of medicinal chemistry
optimization of NUCB1 ligands.
(F) Concentration-dependent blockade of AEA-DA (5 mM) labeling of purified, recombinant NUCB1 (0.25 mM) doped into HEK293T lysates (0.75 mg/ml) by HTS
hit 1 (0.1-100 mM).
(G and H) Structures and competition profiling results (G) and IC50 curves and values (H) for NUCB1 ligands MJN228 and KML110 and the inactive control
compound KML181.
Data in (B) and (H) represent mean values ± SD from at least three independent experiments.of NUCB1 with an IC50 value of 3.3 mM (Figure 6H) and did not
appear to disrupt other arachidonoyl probe-protein interactions
in HEK293T cell lysates (Figure S6E). A second NUCB1-active
ligand was developed that contained a methyl substituent on the
indole nitrogen (22, KML110),which only causeda slight reduction
in potency (IC50 = 9.6 mM), as well as a structurally related inactive
control compound KML181 that displayed markedly reduced po-
tency for NUCB1 (IC50 > 100 mM; Figures 6G and 6H).
We next tested whether the ligands could bind to NUCB1
in cells. Treatment of Neuro2a cells with MJN228 or KML110(25 mM) produced substantial (3- to 5-fold) reductions in lipid
probe enrichment of NUCB1, whereas KML181 had no effect
(Figure 7A). MJN228 inhibited lipid probe binding to NUCB1 at
concentrations as low as 10 mM, with near-maximal inhibition
observed at 25 mM (Figure S7A). A broader analysis of the
lipid-interaction proteome revealed that NUCB1 was the most
competed protein among the 400 AEA-DA probe targets de-
tected in Neuro2a cells (Figure 7B). Finally, we sought to
map the site of arachidonoyl probe (and MJN228) binding to
NUCB1 in cells, which was accomplished by treating Neuro2ACell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc. 1675
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Figure 7. Target Engagement and Lipid Metabolism Effects of NUCB1 Ligands
(A) Representative peptide MS1 chromatograms showing blockade of AEA-DA probe labeling of endogenous NUCB1 in Neuro2a cells by MJN228 and KML110,
but not KML181.
(B) SILAC ratio plot for in situ competition experiment performed with MJN228 (10 mM) and the AEA-DA probe (5 mM).
(C) LC-MS/MS identification of a prominent MJN228-sensitive, AEA-DA-modified NUCB1 peptide (aa 53–68) in Neuro2a cells.
(D) Untargeted metabolite profiling reveals that Neuro2a cells treated with MJN228 (10 mM) show elevated fatty acid amides (NAEs and NATs) compared to cells
treated with DMSO or KML181 (10 mM) (p < 0.0001, n = 5 per condition). See also Table S5.
(E) Targeted MRMmeasurements showing elevations in NAEs in Neuro2a cells treated with NUCB1 ligands MJN228 and KML110 (10 mM, 6 h), but not KML181,
FK-866, or avasimibe. See Figure S7G for MRM measurements of NATs.
(F) Left, western blot showing knockdown of NUCB1 in shNUCB1 A549 cell lines compared to a control cell line (shGFP). Right, both shNUCB1 cells show
significant elevations in NAEs compared to the control shGFP cell line.
(G) NUCB1 ligands MJN228 and KML110 (5 and 25 mM), but not KML181 or FK-866 (25 mM each), suppress the conversion of exogenous AEA (20 mM, 30 min) to
PGF2a-EA in PMA-stimulated A549 cells. Rofecoxib (25 mM) also blocked PGF2a-EA synthesis.
For (E)–(G), data represent mean values ± SEM; n = 3–4/group. *p < 0.05, **p < 0.01, and ***p < 0.001 for DMSO-treated (E) or shGFP cells (F) versus compound-
treated (E) or shNUCB1 (F) cells.cells with the AEA-DA probe (50 mM) in the presence of DMSO or
MJN228 (50 mM), followed by UV irradiation, CuAAC conjugation
of AEA-DA-labeled proteins to isotopically light (DMSO-treated
cells) and heavy (MJN228-treated cells) azide-biotin tags
featuring a TEV protease-cleavable linker, and LC-MS/MS
analysis using a previously described platform, termed iso-
TOP-ABPP, for mapping probe-modified peptides in proteomes
(Speers and Cravatt, 2005). A single prominent AEA-DA-labeled
peptide was identified for NUCB1 (aa 53–68) in DMSO-treated
cells, and the signals for this peptide were substantially
(>5-fold) reduced in MJN228-treated cells (Figure 7C). We1676 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.confirmed this AEA-DA labeling site using recombinant, purified
hNUCB1, and tandemMS analysis narrowed down the likely site
of probe modification to His67 (Figures S7B and S7C). Interest-
ingly, the MJN228-sensitive, AEA-DA-modified peptide resides
within the previously mapped PTGS1/2-binding domain of
NUCB1 (aa 1–123; Figure 7C) (Ballif et al., 1996), indicating
that this region is responsible for both the lipid- and protein-pro-
tein interactions displayed by NUCB1.
Deeper profiling of Neuro2a cells using the isoTOP-ABPP
platform identified AEA-DA-modified peptides for an additional
150 proteins (Table S4), which accounted for40% of the total
AEA-DA targets mapped in this cell line. These findings demon-
strate the potential for chemical proteomics to map not only
lipid-binding proteins, but also the sites on these proteins that
interact with lipids in cells.
NUCB1 Ligands PerturbMultiple Lipid Pathways in Cells
Having established that NUCB1 is a principal target of
MJN228 in cells, we next investigated the metabolic conse-
quences of this ligand-protein interaction by performing a lip-
idomic analysis of Neuro2a cells treated with DMSO, MJN228
(10 mM), or the inactive control probe KML181 (10 mM).
Following a 6 hr incubation with each compound, cells were
harvested and lysed, and their lipids were isolated by organic
extraction and analyzed by untargeted LC-MS in both positive
and negative ion modes. Using XCMS software (Smith et al.,
2006) to quantitate differences between compound- and
DMSO-treated samples, we identified a small group of metab-
olites that were significantly elevated in MJN228-treated
Neuro2a cells (R2-fold, p < 0.0001), but not in cells treated
with KML181 (Figure 7D and Table S5). The chromatographic
and tandem MS profiles of these lipids enabled their structural
assignment as N-acyl ethanolamines (NAEs) and N-acyl
taurines (NATs). NAEs and NATs are hydrolytically metabo-
lized by the enzyme fatty acid amide hydrolase (FAAH)
(Saghatelian et al., 2006); however, neither MJN228 nor
KML110 showed substantial inhibitory activity against purified
recombinant FAAH or endogenous FAAH in Neuro2a lysates
(IC50 values > 100 mM, Figures S7D and S7E), suggesting
that the compounds did not increase NAE or NAT levels
through direct interactions with FAAH in cells. We had also
hoped to directly assess ligand engagement of FAAH in Neu-
ro2a cells using the lipid probes, but we were unable to detect
substantial signals for this enzyme in our chemical proteomic
datasets. The poor labeling of FAAH may be due to the lipid
probes serving as substrates for this enzyme, as we observed
an overall loss in probe labeling of proteins in cells that over-
express FAAH (Figure S7F).
We next used targeted metabolite analysis to evaluate the
effects of NUCB1 ligands and control compounds on the fatty
acid amide content of cells. Both NUCB1 ligands (MJN228 and
KML110), as well as the FAAH inhibitor PF-7845 (Ahn et al.,
2011), elevated the cellular concentrations of NAEs and NATs,
including the endocannabinoid anandamide (C20:4 NAE, or
AEA) and the TRPV4 ligand C20:4 NAT (Saghatelian et al.,
2006) (Figures 7E and S7G). Other arachidonoyl lipids, including
AA and 2-AG, were either unaffected or marginally elevated
by NUCB1 ligands (Figure S7H). Neither KML181, nor the addi-
tional control compounds avasimibe nor FK-866, which shared
many off-targets with the NUCB1 ligands but did not interact
with NUCB1 itself (Figure S7I and Table S2), altered NAE/NAT
content in cells (Figures 7E and S7G). We also confirmed that
the NUCB1 ligands elevated fatty acid amides in a human cell
line (A549 cells; Figure S7J). Finally, we used RNA interference
to stably lower the expression of NUCB1 in A549 cells using
two distinct shRNA probes [shNUCB1(1) and shNUCB1(2)] (Fig-
ure 7F). Multiple NAEs, including AEA and OEA, were elevated in
the shNUCB1-A549 cell lines, but not in the control shRNA
(shGFP-A549) cell line (Figure 7F).Our pharmacological and RNA interference data, taken
together, indicate that NUCB1 plays a role in facilitating the
metabolism of fatty acid amides, possibly by serving as an intra-
cellular carrier to deliver these lipids to FAAH. Consistent with
this model, treatment of cells with both a NUCB1 ligand and
the FAAH inhibitor PF-7845 did not produce larger changes in
NAEs than treatment with the PF-7845 alone (Figure S7K).
AEA is not only a substrate for FAAH, but also PTGS2, which
converts this endocannabinoid into bioactive prostamides
(Rouzer and Marnett, 2011). We therefore tested whether
NUCB1 ligands might also perturb the oxidative metabolism of
AEA by PTGS2. We first confirmed that NUCB1 ligands are not
direct PTGS2 inhibitors (Figure S7L). We then treated PMA-stim-
ulated A549 cells with NUCB1 ligands (MJN228 and KML110)
and control compounds (KML181 and FK-866) followed by
exogenous AEA (20 mM) and measured the formation of prosta-
mides. Both NUCB1 ligands, but not the control compounds,
produced a significant, concentration-dependent reduction in
PGF2a-EA in A549 cells (Figure 7G). Because NUCB1 also
bound AA in our biochemical assays (see Figures 3E and 6B),
we tested whether NUCB1 ligands affected prostaglandin pro-
duction in A549 cells treated with PMA. The PMA-stimulated
generation of PGE2 and, to a lesser degree, TXB2was attenuated
by NUCB1 ligands, but not the control compound KML181 (Fig-
ure S7M). The additional control compound FK-866 exhibited a
curious profile, showing no effect on PGE2 but complete sup-
pression of TXB2 (Figure S7M). It is not clear, however, whether
FK-866 impairs TXB2 production through inhibiting its primary
target NAMPT or another protein in A549 cells. Alterations in
prostamides and prostaglandins were not observed in shNUCB1
cells, which could indicate that a more substantial reduction in
NUCB1 expression than that achieved by RNA-interference is
needed to perturb NUCB1-PTGS2 crosstalk in cells.
DISCUSSION
Many life processes are regulated by the physical interactions
between lipids and proteins, and these interactions constitute
validated nodes for drug action to treat human diseases. None-
theless, our understanding of the full scope of lipid-protein
crosstalk in cells, as well as its accessibility to pharmacological
perturbation, remains limited. Here, we have described a suite of
chemical proteomic probes to inventory the landscape of lipid-
binding proteins and map their ligandability in cells. We focused
on fatty-acid-based probes with limited potential for metabolic
incorporation into more complex lipids, and, in this way, our
studies complement previous work that has inventoried proteins
that bind to other lipid classes (e.g., phospholipids, sterols) (Gal-
lego et al., 2010; Gubbens et al., 2009; Haberkant et al., 2013;
Hulce et al., 2013; Rowland et al., 2011). Key distinguishing fea-
tures of our approach, however, include a comparative assess-
ment of the protein interaction profiles of different structural
lipids, revealing a preferential capacity for arachidonoyl lipids
to interact with proteins, and the adaptation for competitive
profiling to map drug activity across the lipid-interaction prote-
ome. This latter advance not only offers a versatile method for
determining drug-target (and off-target) engagement in cells
but also provides a glimpse into the broader ligandability of theCell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc. 1677
lipid-interaction proteome. That many of the lipid- and drug-
binding proteins discovered herein derive from classes not
known to possess natural or synthetic ligands indicates that
the lipid-interaction proteome should constitute a rich source
for future pharmacological inquiry.
Our studies with NUCB1 establish an experimental framework
for efficiently progressing from the discovery of lipid-binding pro-
teins to the development of selective ligands for the functional
analysis of these proteins. Important to the success of these ef-
forts was the adaptation of the lipid probes for high-throughput
screening of a small-molecule library. We recognize that the
described FluoPol assay may not be straightforward to apply
to all of the lipid-interacting proteins discovered here—in partic-
ular, those that represent multi-pass transmembrane proteins,
which are often difficult to purify and study in solution. Other in-
teractions may reflect binding of lipids to protein complexes that
require careful in vitro reconstitution for further analysis. Regard-
less, we are emboldened by the extent to which the lipid probes
can be applied at each step in the experimental process of map-
ping lipid-regulatory pathways, including target discovery, ligand
screening and optimization, and confirmation of selective target
engagement for optimized ligands in cells.
Our findings also demonstrate how untargeted lipidomics of
cells treated with selective (and control) ligands can provide
initial insights into the biochemical functions of lipid-binding pro-
teins like NUCB1, which may facilitate the intracellular transfer of
NAEs/NATs for delivery to metabolic enzymes, such as FAAH
and PTGS2. Other proteins have been found to contribute to
NAE transport (Kaczocha et al., 2009; Oddi et al., 2009),
including FABP5 (Kaczocha et al., 2009), which was also identi-
fied herein as a target of the arachidonoyl lipid probes. Notably, a
similar mechanism exists for the biosynthesis of leukotrienes,
where the non-enzymatic, auxiliary protein arachidonate 5-lipox-
ygenase activating protein (ALOX5AP or FLAP) facilitates trans-
fer of AA to arachidonate 5-lipoxygenase (ALOX5) (Evans et al.,
2008).
When considering the broader ligandability of the lipid-interac-
tion proteome, it is noteworthy that the drugs assayed herein
showedmarkedly distinct off-target profiles (Figure 5D and Table
S3). This result indicates that the lipid-interaction proteome is
rich and diverse in its ligand-binding content, and the testing of
additional, structurally distinct drugs should uncover even
more ligand-protein interactions. We also observed that the
off-targets for specific drugs, in some cases, share functionality.
The three most potent targets of Ro 48-8071, for instance, were
sequence-unrelated, membrane-bound enzymes (LSS and EBP)
and proteins (TMEM97) involved in the metabolism and regula-
tion cholesterol (Bartz et al., 2009; Laggner et al., 2005; Trapani
et al., 2011), suggesting the potential to develop drugs that
impact multiple nodes in lipid pathways.
We should also mention some of the technical limitations
of mapping lipid- and ligand-binding proteins in cells using
chemical proteomics. There is the potential for false-negative
outcomes in the form of authentic lipid-binding proteins that
fail to interact with the probes due to structural modifications
imposed by the photocrosslinking and alkyne groups. As we
have shown herein, these groups can be located at different
positions on the lipid probes to overcome a negative impact1678 Cell 161, 1668–1680, June 18, 2015 ª2015 Elsevier Inc.on certain protein interactions. One also needs to be aware
of the converse outcome in that we do not expect all lipid
probe-enriched targets to reflect specific-binding interactions.
Distinguishing specific from non-specific binding events can
be facilitated by comparative profiling of structurally distinct
lipid probes or competition experiments with exogenous li-
gands or drugs. It is also possible that some of the drug-depen-
dent changes in lipid probe targets could reflect indirect effects
on protein expression or function. We note, however, that more
than 50% of the liganded proteins discovered herein showed
evidence of interaction with more than one small-molecule
competitor (Table S3). Because the tested ligands target
distinct biochemical pathways, we interpret these data to indi-
cate that most of the decreases in lipid probe labeling likely
reflect primary interactions between competing ligands and
proteins as opposed to secondary effects on protein function
or expression.
In summary, the output of our studies is a global lipid-inter-
action map rich in both known and previously unannotated
lipid-binding proteins, as well as the realization derived from
drug competition profiling experiments that these proteins
constitute a fertile landscape for ligand development. We antic-
ipate that the chemical proteomic methods described herein,
by providing a fully integrated approach to discover both
lipid-binding proteins and selective ligands to perturb the func-
tion of these proteins, will facilitate the characterization of lipid
pathways that make important contributions to human health
and disease.
EXPERIMENTAL PROCEDURES
Materials
Internal standards for LC/MS analysis and competitors were purchased from
Cayman Chemical Company, Sigma-Aldrich, or Avanti Lipids. Lipid probes
and NUCB1 ligands were synthesized according to methods outlined in the
Supplemental Experimental Procedures. UV-mediated crosslinking was
performed on a Stratagene, UV Stratalinker 1800 Crosslinker equipped with
365 nm light bulbs.
Live-Cell Labeling with Clickable Photoaffinity Probes
For gel-based profiling, cells were plated at a density of 2.5 3 106 cells/6 cm
plate and grown for 18–24 hr prior to labeling. The indicated photoaffinity
probe and, if applicable, competitors or vehicle were dissolved in fresh me-
dia (1.5 ml) and warmed to 37C. For competition experiments, serum-free
media were used, whereas standard growth media containing 10% (v/v) fetal
bovine serum (FBS) were used for probe-probe comparisons. The media
from each 6 cm plate were then aspirated, and the cells were washed with
Dulbecco’s phosphate-buffered saline (DPBS) (2 3 3 ml) before adding
media solutions containing probes and competitors. Cells were incubated
at 37C for 30 min before the media were removed, and the cells were
directly exposed to 365 nm light for 10 min at 4C. Alternatively, for no UV
control experiments, probe-treated cells were incubated at 4C for 10 min
in ambient light.
For MS-based experiments, cell labeling was performed in a similar manner
as described above. Modifications to this protocol included using isotopically
light and heavy SILAC cells and increasing the cell count to increase protein
yield. Specifically, SILAC cells were plated at a density of 4 3 106 cells/
10 cm plate and grown to near complete confluency prior to labeling. Addition-
ally, probe and, if applicable, vehicles or competitors were dissolved together
in SILAC media (4.0 ml) with or without dialyzed FBS (10%). Isotopically light
cells were labeled with the arachidinoyl probe (AEA-DA or A-DA) and irradiated
with UV for 10 min at 4C. ‘‘Heavy’’ cells were subjected to variable conditions
as specified in each experiment, including treatments with alternative lipid
probes (OEA-DA, PEA-DA, O-DA, or S-DA) or competitors.
Gel-Based Analysis of Crosslinked Proteins
Cell lysates prepared according to methods described in the Supplemental
Experimental Procedures were diluted to 1.0 mg/ml (total protein concentra-
tion), and 50 ml of each proteome was transferred to separate wells in a 96-
well plate and subjected a freshly prepared ‘‘click’’ reagent mixture containing
TBTA (3.0 ml/sample, 1.7 mM in 4:1 DMSO:t-BuOH), CuSO4 (1.0 ml/sample,
50 mM in H2O), TCEP (1.0 ml/sample, 50 mM in DPBS), and Rh-N3 (1.0 ml/sam-
ple, 1.25 mM in DMSO). After incubating for 1 hr at room temperature, each re-
action was quenched with 43 SDS loading buffer (17 ml), and proteins were
immediately resolved using SDS-PAGE (10% acrylamide gel) and detected
by in-gel fluorescent scanning on a Hitachi FMBIO-II flatbed fluorescence
scanner.
Proteomic Analysis by Mass Spectrometry and Data Analysis
Isotopically heavy and light proteomes derived from probe-labeled cells were
mixed in equal proportions and processed for CuAAC conjugation to biotin-N3,
streptavidin enrichment, and MS-analysis as described in the Supplemental
Experimental Procedures. Proteomic samples were analyzed using a Thermo
Orbitrap Velos mass spectrometer, and the raw data were processed as
described in detail in the Supplemental Experimental Procedures. SILAC
results for identification of UV-dependent probe targets and comparison of
structurally related lipid probes in HEK293T and Neuro2a represent data com-
bined from two to three separate biological replicates. The soluble and mem-
brane fractions from each biological replicate were analyzed separately to
improve protein coverage. Median peptide SILAC ratios were then filtered
to assure that each protein ratio was derived from three or more unique and
quantified peptides and that the combined quantified peptide ratios
possessed a SD of less than 10. SILAC ratios complying with these criteria
were then averaged with ratios acquired from replicates and the alternate frac-
tion (membrane or soluble) to provide a final value, which is reported in Table
S1. If no replicate values were detected, the SILAC ratio from this single occur-
rence was included only if each target was also quantified in probe-versus-
probe experiments according to the above criteria. We reasoned that including
data from instanceswhere a target was identified in a single replicate was justi-
fied based on our analysis of probe-versus-no UV data where we found a
>90% confirmation of UV-dependence (SILAC ratioR 3.0) of targets identified
across multiple replicates. Furthermore, many of these singly quantified
targets were also identified in both cell lines (Neuro2a and HEK293T), further
supporting their legitimacy as lipid probe targets. See Table S1 for a list of in-
dividual peptide sequences, charge states, and ratios detected for each pro-
tein in HEK293T cells. See Supplemental Experimental Procedures for details
on mapping probe-modified peptides in purified NUCB1 and cell proteomes.
UV-dependent lipidprobe targetswere defined as proteins that compliedwith
the following criteria: (1) the protein was identified and quantified (according to
the above criteria) in both probe-versus-probe and probe-versus-no UV data-
sets; (2) the protein exhibited a mean SILAC ratio ofR3.0 in probe-versus-no
UV experiments; (3) the protein exhibited a mean SILAC ratio of <2.0 and >0.5
in probe-versus-probe. Only UV-dependent targets are shown in Table S1. For
competition experiments, only proteins that qualified as UV-dependent targets
according to the above criteria were included in the analysis (see Tables S2
and S3). Furthermore, SILAC ratios for each competition experiment were only
included if they were derived from two or more unique and quantified peptides.
Targeted and Untargeted Lipidomics
Cellular lipids were extracted and analyzed in a similar manner to previously
described methods (Saghatelian et al., 2004). See Supplemental Experimental
Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.05.045.AUTHOR CONTRIBUTIONS
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